BIIB: Biogen Corp Price-to-Revenue Coefficient
Growth for Biogen Inc. (BIIB) is driven by the new products Leqembi and Skyclarys, while the development of gene therapy creates future potential. A team of elite neurobiologists relies on generous scientific funding. The revenue valuation on this precise GURU.Markets chart, where 3.70 shows the current metric value, confirms the brand's status as the leading innovator in the treatment of multiple sclerosis.
Analytical breakdowns for Biogen Corp (BIIB)
- share price and consensus valuation forecast:
- market capitalization information:
- company book value details:
- issuer credit burden and liquidity indicators:
- net income and valuation multiples indicators:
BIIB - Company Net Income|Net Profit Forecast Biogen Inc.|BIIB - P/E Multiple|Projected Price to Earnings Ratio Biogen Inc|BIIB - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Biogen Corp|BIIB - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Biogen|BIIB - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months biogen.com|BIIB - Earnings growth in current year|Net earnings per share growth forecast for next year Biogen Inc.
- issuer revenue and sales details:
General company analysis:BIIB, biogen.com
The P/S multiple compares market capitalization to actual sales volume, allowing for an assessment of the value of each unit of revenue regardless of current profitability. The price-to-sales multiple trend for Biogen Inc. (BIIB) reflects market expectations for new R&D developments in neurology, where the risk of losing patent exclusivity could lead to a sharp devaluation of assets and a reduction in the business's investment attractiveness.
Competing companies
NBIX (neurocrine.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple RGC (Regencell Bioscience Holdings Limited)|Price-to-Revenue Coefficient Axsome (AXSM)|ACAD - Price-to-Revenue Ratio|XENE (Xenon Corp) - Market Cap to Revenue Ratio|VKTX: P/S Multiple|Market Cap to Revenue supernus.com|Market Cap to Revenue CPRX|Denali (DNLI) - Price-to-Revenue Coefficient|P/S Multiple HRMY|Price-to-Revenue Ratio BHVN (Biohaven Corp)|P/S Multiple AMLX (Amylyx Pharmaceuticals)|Price-to-Revenue Coefficient trevitherapeutics.com (TRVI)|Praxis Precision Medicines, Inc. - P/S Multiple|Price-to-Revenue Coefficient Anavex AVXL|CBLL: P/S Multiple|PRTA (Prothena Corp) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Alector Inc.|Market Cap to Revenue Ratio ANNX (annexonbio.com)|P/S Multiple OMER|NGNE - Price to Sales|AC Immune Corp - Market Cap to Revenue|P/S Multiple Voyager Corp VYGR|NMRA - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio SCLX (scilexholding.com)|Tevogen Bio (TVGN) - Price-to-Revenue Ratio|Price to Sales Alpha Cognition Inc. (ACOG)|CGTX (Cognition Therapeutics, Inc.) - P/S Multiple|Price-to-Revenue Ratio IKT|P/S Multiple SAVA|Price-to-Revenue Coefficient assertiotx.com|Price-to-Revenue Ratio Coya Therapeutics COYA|VistaGen Therapeutics, Inc. (VTGN) - Price to Sales|Ovid Rx - P/S Multiple|Price-to-Revenue Multiple Acumen Pharmaceuticals, Inc (ABOS)|CRVO: P/S Multiple|Price to Sales Alterity Therapeutics Limited (ATHE)|Price-to-Revenue Ratio Clene Inc|Market Cap to Revenue Ratio PEPG (PepGen Corp)|Market Cap to Revenue JUNS (Jupiter Neurosciences)|RLMD (Relmada Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple ANVS (Annovis Bio, Inc.)|Price-to-Revenue Coefficient Grace Therapeutics Inc (GRCE)|AIFF - Price-to-Revenue Ratio|KLTO (Klotho Neurosciences Inc) - Market Cap to Revenue Ratio|NRSN: P/S Multiple|Market Cap to Revenue Reviva Pharmaceuticals, Inc.|Market Cap to Revenue MTVA|neuraxis.com (NRXS) - Price-to-Revenue Coefficient|P/S Multiple HSDT|Price-to-Revenue Ratio PASG (passagebio.com)|P/S Multiple NEUP (Neuphoria Therapeutics)|Price-to-Revenue Coefficient Minerva (NERV)|Athira Pharma, Inc. - P/S Multiple|Price-to-Revenue Coefficient addextherapeutics.com ADXN|ALZN: P/S Multiple|CYCN (Cyclerion Therapeutics, Inc.) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Protagenic Therapeutics Inc.|Market Cap to Revenue Ratio KTTA (Pasithea)|P/S Multiple CRGT|ATXI - Price to Sales|BrainStorm Cell Therapeutics - Market Cap to Revenue|P/S Multiple Cara Therapeutics Inc. CARA|CHRO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ELYM (Eliem Therapeutics)|intracellulartherapies.com (ITCI) - Price-to-Revenue Ratio|Price to Sales longboardpharma.com (LBPH)|MRNS (Marinus Pharmaceuticals, Inc.) - P/S Multiple|Price-to-Revenue Ratio NKGN|P/S Multiple NRBO|Price-to-Revenue Coefficient Sage Therapeutics Inc|Price-to-Revenue Ratio Synaptogenix, Inc. SNPX|trevena.com (TRVN) - Price to Sales|Vigil Neuro - P/S Multiple|Price-to-Revenue Multiple anewmeds.com (WENA)|CERE: P/S Multiple
